세계의 소화불량 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Dyspepsia Drugs Market is presumed to reach the market size of nearly USD 16.41 BN by 2032 from USD 10.3 BN in 2023 with a CAGR of 5.31% under the study period 2024 - 2032.

Dyspepsia drugs refer to medications or pharmaceutical treatments used to alleviate the symptoms of dyspepsia, a common digestive disorder characterized by discomfort or pain in the upper abdomen. Dyspepsia, often referred to as indigestion, can manifest with symptoms such as bloating, belching, nausea, and a feeling of fullness during or after meals. These drugs aim to relieve these symptoms and improve overall digestive well-being.

MARKET DYNAMICS

The Dyspepsia drugs market is driven by factors rooted in the prevalence of dyspepsia, a common digestive ailment characterized by symptoms like abdominal discomfort and indigestion. Modern lifestyles, including irregular eating habits and high-stress levels, contribute to the occurrence of dyspeptic symptoms, propelling the demand for drugs offering relief. Gastrointestinal disorders, such as GERD and peptic ulcers, often coexist with dyspepsia, further boosting the market. Aging populations and changing dietary habits contribute to the global demand, particularly among the elderly. Increased awareness, improved diagnostics, and over-the-counter availability of certain medications play pivotal roles in driving market growth. Ongoing technological advancements in drug development, a focus on combination therapies, and a patient-centric approach in healthcare further contribute to the dynamic landscape of the dyspepsia drugs market. As individuals seek effective pharmacological solutions for digestive discomfort, the market responds with innovative formulations and tailored treatments to meet diverse patient needs.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of dyspepsia drugs. The growth and trends of dyspepsia drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the dyspepsia drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Indication

• Functional Dyspepsia
• Organic Dyspepsia

By Drug Type

• Proton Pump Inhibitors
• H-2-Receptor Antagonists
• Antacids
• Antibiotics
• Prokinetics
• Antidepressants

By Medication

• Branded
• Generic

By Mode

• Over-The-Counter
• Prescription

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Dyspepsia Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Dyspepsia Drugs market include Takeda Pharmaceutical Company Limited, AstraZeneca plc, Salix Pharmaceuticals Inc., Abbott Laboratories, Pfizer Inc., Sanofi SA, Procter & Gamble, Haleon plc, ANI Pharmaceuticals Inc., Dr Reddy's Laboratories Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . DYSPEPSIA DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Indication
  • 3.7.2 Market Attractiveness Analysis By Drug Type
  • 3.7.3 Market Attractiveness Analysis By Medication
  • 3.7.4 Market Attractiveness Analysis By Mode
  • 3.7.5 Market Attractiveness Analysis By Distribution Channel
  • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL DYSPEPSIA DRUGS MARKET ANALYSIS BY INDICATION

• 5.1 Overview by Indication
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Indication
• 5.4 Functional Dyspepsia Historic and Forecast Sales by Regions
• 5.5 Organic Dyspepsia Historic and Forecast Sales by Regions

6 . GLOBAL DYSPEPSIA DRUGS MARKET ANALYSIS BY DRUG TYPE

• 6.1 Overview by Drug Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Drug Type
• 6.4 Proton Pump Inhibitors Historic and Forecast Sales by Regions
• 6.5 H-2-receptor Antagonists Historic and Forecast Sales by Regions
• 6.6 Antacids Historic and Forecast Sales by Regions
• 6.7 Antibiotics Historic and Forecast Sales by Regions
• 6.8 Prokinetics Historic and Forecast Sales by Regions
• 6.9 Antidepressants Historic and Forecast Sales by Regions

7 . GLOBAL DYSPEPSIA DRUGS MARKET ANALYSIS BY MEDICATION

• 7.1 Overview by Medication
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Medication
• 7.4 Branded Historic and Forecast Sales by Regions
• 7.5 Generic Historic and Forecast Sales by Regions

8 . GLOBAL DYSPEPSIA DRUGS MARKET ANALYSIS BY MODE

• 8.1 Overview by Mode
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Mode
• 8.4 Over-the-counter Historic and Forecast Sales by Regions
• 8.5 Prescription Historic and Forecast Sales by Regions

9 . GLOBAL DYSPEPSIA DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 9.1 Overview by Distribution Channel
• 9.2 Historical and Forecast Data
• 9.3 Analysis by Distribution Channel
• 9.4 Retail Pharmacies Historic and Forecast Sales by Regions
• 9.5 Hospital Pharmacies Historic and Forecast Sales by Regions
• 9.6 Online Pharmacies Historic and Forecast Sales by Regions

10 . GLOBAL DYSPEPSIA DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2. North America By Segment Sales Analysis
  • 10.3.3. North America By Country Sales Analysis
  • 10.3.4. United State Sales Analysis
  • 10.3.5. Canada Sales Analysis
  • 10.3.6. Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2. Europe by Segment Sales Analysis
  • 10.4.3. Europe by Country Sales Analysis
  • 10.4.4. United Kingdom Sales Analysis
  • 10.4.5. France Sales Analysis
  • 10.4.6. Germany Sales Analysis
  • 10.4.7. Italy Sales Analysis
  • 10.4.8. Russia Sales Analysis
  • 10.4.9. Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2. Asia Pacific by Segment Sales Analysis
  • 10.5.3. Asia Pacific by Country Sales Analysis
  • 10.5.4. China Sales Analysis
  • 10.5.5. India Sales Analysis
  • 10.5.6. Japan Sales Analysis
  • 10.5.7. South Korea Sales Analysis
  • 10.5.8. Australia Sales Analysis
  • 10.5.9. South East Asia Sales Analysis
  • 10.5.10. Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2. Latin America by Segment Sales Analysis
  • 10.6.3. Latin America by Country Sales Analysis
  • 10.6.4. Brazil Sales Analysis
  • 10.6.5. Argentina Sales Analysis
  • 10.6.6. Peru Sales Analysis
  • 10.6.7. Chile Sales Analysis
  • 10.6.8. Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2. Middle East & Africa by Segment Sales Analysis
  • 10.7.3. Middle East & Africa by Country Sales Analysis
  • 10.7.4. Saudi Arabia Sales Analysis
  • 10.7.5. UAE Sales Analysis
  • 10.7.6. Israel Sales Analysis
  • 10.7.7. South Africa Sales Analysis
  • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE DYSPEPSIA DRUGS COMPANIES

• 11.1. Dyspepsia Drugs Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12 . COMPANY PROFILES OF DYSPEPSIA DRUGS INDUSTRY

• 12.1. Company Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Takeda Pharmaceutical Company Limited
  • 12.3.1. Company Overview
  • 12.3.2. Company Revenue
  • 12.3.3. Products
  • 12.3.4. Recent Developments
• 12.4. AstraZeneca plc.
  • 12.4.1. Company Overview
  • 12.4.2. Company Revenue
  • 12.4.3. Products
  • 12.4.4. Recent Developments
• 12.5. Salix Pharmaceuticals Inc.
  • 12.5.1. Company Overview
  • 12.5.2. Company Revenue
  • 12.5.3. Products
  • 12.5.4. Recent Developments
• 12.6. Abbott Laboratories
  • 12.6.1. Company Overview
  • 12.6.2. Company Revenue
  • 12.6.3. Products
  • 12.6.4. Recent Developments
• 12.7. Pfizer Inc.
  • 12.7.1. Company Overview
  • 12.7.2. Company Revenue
  • 12.7.3. Products
  • 12.7.4. Recent Developments
• 12.8. Sanofi SA
  • 12.8.1. Company Overview
  • 12.8.2. Company Revenue
  • 12.8.3. Products
  • 12.8.4. Recent Developments
• 12.9. Procter & Gamble
  • 12.9.1. Company Overview
  • 12.9.2. Company Revenue
  • 12.9.3. Products
  • 12.9.4. Recent Developments
• 12.10. Haleon plc
  • 12.10.1. Company Overview
  • 12.10.2. Company Revenue
  • 12.10.3. Products
  • 12.10.4. Recent Developments
• 12.11. ANI Pharmaceuticals Inc.
  • 12.11.1. Company Overview
  • 12.11.2. Company Revenue
  • 12.11.3. Products
  • 12.11.4. Recent Developments
• 12.12. Dr Reddy's Laboratories Ltd.
  • 12.12.1. Company Overview
  • 12.12.2. Company Revenue
  • 12.12.3. Products
  • 12.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies